| 12.05 0.25 (2.12%) | 08-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 15.28 |
1-year : | 17.85 |
| Resists | First : | 13.09 |
Second : | 15.28 |
| Pivot price | 11.62 |
|||
| Supports | First : | 11.61 |
Second : | 10.71 |
| MAs | MA(5) : | 11.69 |
MA(20) : | 11.62 |
| MA(100) : | 13.06  |
MA(250) : | 15.58 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 60.4 |
D(3) : | 53.7 |
| RSI | RSI(14): 54.6 |
|||
| 52-week | High : | 36.25 | Low : | 4.46 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ OLMA ] has closed below upper band by 6.3%. Bollinger Bands are 75.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 18 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 12.22 - 12.31 | 12.31 - 12.37 |
| Low: | 11.34 - 11.43 | 11.43 - 11.5 |
| Close: | 11.68 - 11.82 | 11.82 - 11.93 |
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.
Sat, 08 Aug 2026
Dimensional Fund Advisors LP Acquires 123,790 Shares of Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Thu, 06 Aug 2026
FMR LLC, Abigail Johnson disclose 13.8% Olema Pharmaceuticals (OLMA) ownership - Stock Titan
Tue, 04 Aug 2026
Seven New Hires Get Olema Stock Options at $11.28 a Share - Stock Titan
Tue, 04 Aug 2026
OLMA Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Tue, 04 Aug 2026
Have Olema Pharmaceuticals Insiders Been Selling Stock? - webull.com
Mon, 03 Aug 2026
Defilade Capital Management L.P. Acquires 269,902 Shares of Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 87 (M) |
| Shares Float | 64 (M) |
| Held by Insiders | 1.7 (%) |
| Held by Institutions | 119.2 (%) |
| Shares Short | 15,100 (K) |
| Shares Short P.Month | 12,840 (K) |
| EPS | -2.03 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.5 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -25.5 % |
| Return on Equity (ttm) | -42.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.2 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -149 (M) |
| Levered Free Cash Flow | -79 (M) |
| PE Ratio | -5.94 |
| PEG Ratio | 0 |
| Price to Book value | 2.19 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.08 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|